JNJ up +0.42% percent Today $JNJ High is at 108.69 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
JNJ up +0.42% percent Today $JNJ High is at 108.69 and the Low 107.61 with current volume of 894,784.

Recent News posted below.

Johnson & Johnson JNJ other info.
http://investorshangout.com/Johnson--Johnson-JNJ-51518/

JNJ Johnson & Johnson Recent Headline News

DexCom Still A Favorite Diabetes Stock
Bill Gunderson - at Seeking Alpha - 2 hrs 17 mins ago
DexCom (NASDAQ: DXCM ) continues to be one of my favorite diabetes stocks. DexCom, founded in 1999 and based right here in my hometown of San Diego, California, is a medical device company that makes continuous glucose monitoring (CGM) systems. ...
JNJ: 108.30 (+0.14), ABT: 43.90 (+0.09), DXCM: 52.34 (-0.39), MDT: 69.54 (+0.59)

Early Glance: Medical Devices companies
AP - Mon Nov 17, 9:29AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.73 (+0.61), JNJ: 108.30 (+0.14), MDT: 69.54 (+0.59), BAX: 71.99 (+0.24)

Early Glance: Pharmaceuticals companies
AP - Mon Nov 17, 9:29AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.30 (+0.14), BAX: 71.99 (+0.24), PFE: 30.32 (-0.02), BMY: 58.21 (+0.26)

5 Rocket Stocks to Buy as Earnings Season Ends: Southwest Airlines and More
at The Street - Mon Nov 17, 9:17AM CST
From a momentum standpoint, stocks are well-positioned to keep up their upside action as we head into the final stretch of 2014.
JNJ: 108.30 (+0.14), ORLY: 177.64 (-2.24), ED: 62.52 (+0.49), LUV: 39.45 (+0.50), CRM: 62.82 (-1.09)

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.30 (+0.14), GILD: 100.44 (-1.62), ABBV: 65.14 (+1.14), CELG: 104.66 (+0.61)

Forget Marijuana! This Is a Much Smarter Investment
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 16, 11:11AM CST
Source: Flickr user Oswaldo. Although marijuana initiatives didn't log a perfect sweep in this year's midterm elections, the momentum behind the legalization movement remains intact. Two states (Oregon and Alaska), as well as Washington, D.C.,...
JNJ: 108.30 (+0.14), INSY: 38.50 (-0.07), GWPH: 75.31 (-0.32), GSK: 45.93 (+0.19), NVS: 94.54 (+0.59)

Value Investors' Most Loved Stocks In Q3 2014
Trading Mates Stock Advisor - at Seeking Alpha - Sun Nov 16, 8:09AM CST

NOV: 71.80 (+0.46), JNJ: 108.30 (+0.14), IBM: 164.48 (+0.32), WMT: 83.51 (+0.55), BAC: 17.07 (-0.07), BEN: 56.30 (-0.08), ACN: 84.69 (+0.05), SLB: 95.98 (+0.66), ORCL: 41.18 (+0.34)

3 Ways High-Yield Dividend Stocks Can Help You Recreate Warren Buffett's Investing Success
Adam Galas, The Motley Fool - Motley Fool - Sat Nov 15, 6:05PM CST
Many people consider Warren Buffett the greatest investor in history and it's not hard to understand why. According to a 2012 Yale study, Buffett's company, Berkshire Hathaway , had the best risk-adjusted return of any company or mutual fund that...
KMI: 39.99 (+0.62), MMM: 159.04 (+0.19), JNJ: 108.30 (+0.14), LNCO: 20.39 (-0.54), IBM: 164.48 (+0.32), WFC: 53.39 (+0.04), SDRL: 20.86 (+0.08), PG: 87.78 (-0.33), LINE: 22.37 (-0.28), VNR: 23.93 (-0.55), CL: 67.81 (+0.25)

Johnson & Johnson Part VI: 'Magic Pants' And 'Doubling Pennies'
Robert Honeywill - Seeking Alpha - Sat Nov 15, 6:00AM CST
In Part V of this series, I provided 4 scenarios (8 Cases) illustrating the potential financial outcomes for investors in Johnson & Johnson (NYSE: JNJ ) under changing PE ratios, which are a reflection of changing share prices and changing...
JNJ: 108.30 (+0.14)

Retirement Strategy: Annuities Vs. Dividend Growth Investing For A Lifetime Income
Regarded Solutions - at Seeking Alpha - Fri Nov 14, 11:01PM CST

KO: 42.94 (+0.21), T: 35.90 (unch), JNJ: 108.30 (+0.14), GE: 26.65 (+0.19), XOM: 95.04 (-0.05), MCD: 95.84 (-0.37), PG: 87.77 (-0.34), CVX: 115.98 (-0.34), AAPL: 114.00 (-0.18), WAG: 66.24 (-0.69)

Final Glance: Pharmaceuticals companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.30 (+0.14), BAX: 71.99 (+0.24), PFE: 30.32 (-0.02), BMY: 58.21 (+0.26)

Final Glance: Medical Devices companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.73 (+0.61), JNJ: 108.30 (+0.14), MDT: 69.53 (+0.58), BAX: 71.99 (+0.24)

Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 304.67 (-0.76), JNJ: 108.30 (+0.14), GERN: 3.02 (+0.26), AFFX: 9.39 (-0.32)

Halliburton and Geron are big market movers
AP - Fri Nov 14, 3:29PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SINA: 39.30 (-0.50), AMZN: 321.03 (-6.79), JNJ: 108.30 (+0.14), HTZ: 22.17 (+0.48), GERN: 3.02 (+0.26), HAL: 49.82 (-5.26), JWN: 73.33 (-0.84), NOK: 7.66 (-0.20), BHI: 66.27 (+6.38)

Geron's Short Squeeze Is Here
Vahan Avetisyan - Seeking Alpha - Fri Nov 14, 2:40PM CST
Geron' s 2014 D eal to the Rescue Geron (NASDAQ: GERN ) surprised Thursday after-hours when it announced news that it entered into an exclusive worldwide license and collaboration agreement to develop its blood disorder drug imetelstat with...
JNJ: 108.30 (+0.14), GERN: 3.02 (+0.26)

Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.39 (+0.28), BIIB: 304.67 (-0.76), JNJ: 108.30 (+0.14), ACT: 247.01 (+3.24)

Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline
at The Street - Fri Nov 14, 2:36PM CST
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 39.30 (-0.50), JNJ: 108.30 (+0.14), HTZ: 22.17 (+0.48), VA: 30.98 (+0.98), GERN: 3.02 (+0.26), JWN: 73.33 (-0.84)

Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.30 (+0.14), BAX: 71.99 (+0.24), PFE: 30.32 (-0.02), BMY: 58.21 (+0.26)

Midday Glance: Medical Devices companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.73 (+0.61), JNJ: 108.30 (+0.14), MDT: 69.53 (+0.58), BAX: 71.99 (+0.24)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 5

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 7

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 6

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading

Top 5 Most Recently Viewed Articles

NuScale Power Corp: Evaluating Investor Sentiment and Trends

Updated Category News Views 187

Understanding NuScale Power Corp's Current Investment Landscape NuScale Power Corp (NYSE: SMR) has recently seen a notable decline in short interest, dropping by 12.04% according to the latest reports. Currently, there are 32.51 million shares that have been sold short, representing 19.5% of all available trading shares. Given the current trading volume, it is estimated...

Continue Reading
Criminal Allegations Linked to Defective Boeing Aircraft Parts

Updated Category News Views 200

Allegations Against Individuals and Firms Recent news from Italy reveals that prosecutors have charged seven individuals and two subcontracting firms with serious offenses, including fraud and violations of aircraft safety regulations. This development comes following a detailed investigation into potentially defective aircraft parts manufactured for Boeing. Investigation...

Continue Reading
Perrigo Company Faces Class Action: Important Investor Update

Updated Category News Views 118

Overview of the Class Action Against Perrigo Company plc Perrigo Company plc, a prominent player in the pharmaceutical and healthcare industry, is currently involved in a significant class action lawsuit that has drawn the attention of investors. The class action, led by the legal firm Levi & Korsinsky, seeks to represent the interests of those who have incurred losses...

Continue Reading
Cybastion Launches Program to Enhance Digital Budget in Africa

Updated Category News Views 235

Cybastion Unveils Digital Fast Track Program for Africa In a significant step towards enhancing U.S. commercial diplomacy, Cybastion has launched the Digital Fast Track program. This initiative, created in collaboration with prominent American technology firms, aims to revolutionize digital infrastructure in Africa, facilitating greater U.S. business engagement and...

Continue Reading
Corgan Welcomes Ian Zapata as New Director of Design

Updated Category News Views 376

Ian Zapata Takes the Helm as Director of Design at Corgan Global architecture and design firm Corgan is proud to announce the appointment of Ian Zapata as the new Director of Design. With an impressive background spanning over 25 years, Zapata is set to elevate the firm's design ethos while emphasizing innovation and sustainability. A Design Journey That Comes Full Circle...

Continue Reading